Company Filing History:
Years Active: 2002
Title: Innovations by Andreas Schulze
Introduction
Andreas Schulze is a notable inventor based in Aesch, Switzerland. He has made significant contributions to the field of electrochemical measurement, particularly in the area of protease activity. His innovative work has led to the development of a unique patent that addresses important challenges in enzyme determination.
Latest Patents
Andreas Schulze holds a patent for "Oligopeptide derivatives for the electrochemical measurement of protease activity." This invention involves oligopeptide derivatives whose C-terminal amino acid is arginine, linked to an electroactive aniline or aminoquinoline derivative by an amide bond. These derivatives are designed to be split by enzymes of the peptide hydrolase class, particularly proteinases and their inhibitors, which are crucial in various biological systems. The oligopeptide derivatives serve as substrates for quantitatively determining enzymes, especially thrombin, in complex sample liquids, such as capillary blood. The determination process involves measuring the increase in the water-soluble amperogenic aniline or aminoquinoline compound. The production of these oligopeptide derivatives and their salts follows established methods in peptide chemistry.
Career Highlights
Andreas Schulze is associated with Pentapharm AG, a company that focuses on innovative solutions in the field of biochemistry and pharmaceuticals. His work at Pentapharm AG has allowed him to explore and develop groundbreaking technologies that enhance the understanding and measurement of protease activity.
Collaborations
Andreas has collaborated with notable colleagues, including Christian Ludin and Peter Wikstroem. These collaborations have contributed to the advancement of research and development in their respective fields.
Conclusion
Andreas Schulze's innovative contributions to the field of electrochemical measurement and protease activity highlight his role as a significant inventor. His patent and work at Pentapharm AG demonstrate the impact of his research on the scientific community.